Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059736 | 0.89 | GRIN2B (0.53) | GRIN2BHDAC1BCL2NAMPTGSK3B | |
| SCHEMBL28653645 | 0.88 | GRIN2B (0.53) | GRIN2BHDAC1BCL2NAMPTGSK3B | |
| SCHEMBL13838587 | 0.86 | GRIN2B (0.52) | GRIN2BHDAC1BCL2NAMPTGSK3B | |
| SCHEMBL31727242 | 0.84 | GRIN2B (0.48) | GRIN2BHDAC1BCL2NAMPTGSK3B | |
| SCHEMBL29651977 | 0.84 | HCAR3 (0.57) | GRIN2BHDAC1BCL2HCAR3 | |
| SCHEMBL2877186 | 0.84 | HCAR3 (0.57) | GRIN2BHDAC1BCL2HCAR3 | |
| SCHEMBL28658285 | 0.84 | GRIN2B (0.48) | GRIN2BHDAC1BCL2NAMPTGSK3B | |
| SCHEMBL30552385 | 0.83 | HDAC1 (0.51) | GRIN2BHDAC1BCL2NAMPTGSK3B | |
| SCHEMBL26227296 | 0.83 | HDAC1 (0.51) | GRIN2BHDAC1BCL2NAMPTGSK3B | |
| SCHEMBL7936803 | 0.83 | HCAR3 (0.55) | GRIN2BHDAC1BCL2HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | NANTBIO, INC. | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | IL5, IKZF3, CYP11B2 | GRIN2B 370/4885HDAC1 112/4885BCL2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.